PubRank

Argyris Michalopoulos

Author PubWeight™ 46.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest 2005 3.58
2 Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005 2.47
3 β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011 2.03
4 Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007 1.89
5 Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005 1.89
6 Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2009 1.88
7 Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005 1.70
8 Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008 1.69
9 Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005 1.60
10 Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 2008 1.56
11 Microbiologically documented nosocomial infections after coronary artery bypass surgery without cardiopulmonary bypass. J Thorac Cardiovasc Surg 2006 1.45
12 Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005 1.40
13 Cefuroxime as antibiotic prophylaxis in coronary artery bypass grafting surgery. Interact Cardiovasc Thorac Surg 2007 1.39
14 Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008 1.36
15 Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005 1.36
16 Patterns and early evolution of organ failure in the intensive care unit and their relation to outcome. Crit Care 2012 1.26
17 Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2005 1.20
18 The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006 1.14
19 Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect 2007 1.09
20 Outcome of critically ill oldest-old patients (aged 90 and older) admitted to the intensive care unit. J Am Geriatr Soc 2006 1.04
21 Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006 1.03
22 Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med 2008 0.95
23 Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates. Int J Antimicrob Agents 2007 0.94
24 Infections of respiratory or abdominal origin in ICU patients: what are the differences? Crit Care 2010 0.91
25 Aspergillus fumigatus tricuspid native valve endocarditis in a non-intravenous drug user. J Med Microbiol 2006 0.90
26 Rhinocerebral mucormycosis in a patient with cirrhosis and chronic renal failure. Hepatogastroenterology 2003 0.88
27 Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit Care 2006 0.86
28 Polymyxins: old antibiotics are back. Lancet 2006 0.86
29 Is plasma calcium concentration implicated in the development of critical illness polyneuropathy and myopathy? Crit Care 2011 0.84
30 Plesiomonas shigelloides sepsis in a thalassemia intermedia patient. Scand J Infect Dis 2002 0.84
31 Alterations in biomarkers of endothelial function following on-pump coronary artery revascularization. J Clin Lab Anal 2010 0.79
32 Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia. PLoS One 2011 0.78
33 Treatment of acute bacterial exacerbations of chronic bronchitis. Expert Opin Pharmacother 2009 0.78
34 Knowledge and practices regarding prevention of infections associated with central venous catheters: a survey of intensive care unit medical and nursing staff. Am J Infect Control 2011 0.77
35 Nosocomial infections after off-pump coronary artery bypass surgery: frequency, characteristics, and risk factors. Interact Cardiovasc Thorac Surg 2007 0.76
36 The significance of different formulations of aerosolized colistin. Crit Care 2005 0.76
37 Inadequate statistical power of published comparative cohort studies on ventilator-associated pneumonia to detect mortality differences. Clin Infect Dis 2010 0.76
38 Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis 2011 0.75
39 Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2006 0.75
40 Open-access world wide web resources on sepsis. Clin Infect Dis 2008 0.75
41 Polymyxins: a word of caution for prudent use of valuable "old antibiotics". Infect Control Hosp Epidemiol 2006 0.75
42 Predictors of early postoperative atrial fibrillation after off-pump myocardial revascularization. Innovations (Phila) 2007 0.75
43 Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. Expert Rev Anti Infect Ther 2008 0.75
44 Trimethoprim/sulfametrole: evaluation of the available clinical and pharmacokinetic/pharmacodynamic evidence. Int J Antimicrob Agents 2011 0.75
45 Pulmonary drug delivery systems for antimicrobial agents: facts and myths. Int J Antimicrob Agents 2009 0.75
46 Treatment of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii pneumonia. J Cyst Fibros 2005 0.75